Karyopharm Therapeutics (KPTI) PT Lowered to $6 at Wedbush, Following Earnings
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $2.02 +1.51%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush analyst David Nierengarten lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $6.00 (from $11.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
